MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Casdin Capital
Finance & Acquisitions: Casdin
Parents
Casdin Capital
Children
2014: Invitae has raised $87 million from investors, including Thomas, McNerney & Partners, Genomic Health, Inc. (NASDAQ: GHDX), Genesys Capital, Casdin Capital, Redmile Group and Randy Scott. (2013)
2018: Others joining Relay’s latest financing include new investors Foresite Capital, Perceptive Advisors, and Tavistock Group. Earlier investors GV, Casdin Capital, BVF Partners, EcoR1 Capital, an affiliate of D. E. Shaw Research, and Alexandria Venture Investments also participated in the round.
2018: The company raised $45 million in a new financing round including Tenaya Capital, Glynn Capital Partners, Crown Ventures, and Casdin Capital. Existing investors that include Greylock Partners, Venrock, and Providence Ventures
2020: Initial financing provided by Perceptive Advisors, RA Capital, Venrock Healthcare Capital Partners, Chinese investor CMG-SDIC Capital, BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer Inc., Sphera Healthcare, funds and accounts advised by T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors and Wellington Management
2020: New investors Wellington Management and Casdin Capital also joined the round.
2020: Round led by Casdin Capital and by Danaher Life Sciences, Agilent Technologies, Merck KGaA, through its corporate venture arm, M Ventures, LSP, the Bpifrance Large Venture Fund and Illumina Ventures.
2020: The latest funding round was led by Addition and joined by Adams Street Partners and existing investors, including Starbucks chairman emeritus and former CEO Howard Schultz, Casdin Capital, Glynn Capital, Greylock Partners, IVP, Meritech Capital Partners, Providence Ventures, and Tenaya Capital.
2020: The Series A was led by Third Rock Ventures with Novartis Venture Fund, Eli Lilly and Company, AbbVie Ventures, Invus, Catalio Capital Management, Casdin Capital and Alexandria Venture Investments
2020: The Series C extension is led by Cardinal Health, with participation from Marc Benioff and existing Vineti investors, including Canaan Partners, Threshold Ventures (formerly DFJ), Section 32, Casdin Capital, Novartis Pharma AG, McKesson Ventures, and LifeForce Capital
2020: Third Rock Ventures, announced that New York investment firm Casdin Capital and San Diego area-based venture firm Section 32 had co-led its Series B round
2021: $100 million series C round this past January raised funds from Casdin Capital and Johnson & Johnson Innovation, while a months-long series B round last year gathered up to $70 million from Goldman Sachs, Healthcare Venture Partners and others.
2021: Amunix’s Series B investors include Redmile Group, Venrock, Casdin Capital, Omega Funds, Frazier Healthcare Partners, Longitude Capital, Polaris Partners, Viking Global Investors, Bain Capital Life Sciences and BlackRock
2021: Andreessen, Madrona, and Vulcan participated in the PIPE, as well as new backers such as RA Capital Management, Ally Bridge Group, Bain Capital Life Sciences, Franklin Templeton Investments, OrbiMed, Alyeska Investment Group, L.P., and Casdin Capital.
2021: ARCH Venture Partners and Versant led a $135 million raise with Logos Capital, Boxer Capital, SoftBank, Avoro Capital Advisors, BlackRock, RA Capital Management, T. Rowe Price Associates, Surveyor Capital (a Citadel company), Woodline Partners LP, Acuta Capital, Driehaus Capital Management, BVF Partners L.P., Casdin Capital, Mubadala Capital, and Nextech Invest.
2021: Lyra Health’s current valuation is $2.3 billion, having raised $284.1 million from Adams Street Partners Addition Breyer Capital Castlight Health and Casdin Capital, amongst others, the latter of which is invested in both IPOC/CLOV and VGAC SPACs.
2021: Series C financing was led by Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. (JJDC), the strategic venture capital arm of Johnson & Johnson
2021: Series C round led by RTW Investments, LP, RA Capital Management, Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., The Column Group, Casdin Capital and GV.
2021: The PIPE was led by a $100 million investment from Palihapitiya and $50 million from Hedosophia, as well as commitments from Fidelity Management & Research Company and funds affiliated with Jennison, Senator Investment Group LP, Casdin Capital and Perceptive Advisors.
Investors participating in the Series E round include Genomic Health, Inc. (GHDX), Randy Scott, Thomas McNerney & Partners, Redmile Group, Genesys Capital, Casdin Capital, among others.
New round includes Deerfield Management Company, Casdin Capital, Redmile Group and an undisclosed fund.
Omicia has picked up a $6.8 million series A led by Artis Ventures, Buchannan Investments, Bay City Capital, as well as Acadia Woods Partners and Casdin Capital
Portfolio Companies: Casdin Capital
Third Rock Ventures Led Financing Together with Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, Invus, Exact Sciences and Others
Jumps
*Key People: Casdin